Celgene stock has formed a great looking consolidation or basing pattern after dropping -35% on news that was not too bad. I think we have a great bottom feeder play here.
Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
BeiGene stock has large players volume exploding higher. The company reported eye-popping earnings and revenue beats this week.
Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.
Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock. Verastem is on track for duvelisib
Incyte Corporation stock has rising large players volume in an Ascending Triangle pattern. The large players volume rising while Incyte has been consolidating is a bullish pattern. Incyte Corporation Stock
Sorrento Therapeutics Inc has bounced off its 61.8 percent Fibonacci retracement level. Sorrento Therapeutics had a decline in short interest in the month of September. As of September 29th, there
ContraVir Pharmaceuticals stock had short covering ahead of a price target hike by Maxim Group. A new $4 price target was set by analysts at Maxim Group on Thursday, October
Global Blood Therapeutics stock has excellent large players volume action. Large players volume is in an uptrend and is confirmed by the rising Twiggs Money Flow. Global Blood Therapeutics stock has